AstraZeneca Proposes $10 Billion Acquisition of Rhythm Pharmaceuticals
AstraZeneca has submitted a non-binding offer to acquire obesity drug developer Rhythm Pharmaceuticals for approximately $10 billion.
Stocks · News reference
AlphaValue/Baader Europe Downgrades AstraZeneca to Reduce
AlphaValue/Baader Europe has downgraded its rating on AstraZeneca from 'Add' to 'Reduce'.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Makes $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly submitted a $10 billion takeover offer to acquire Rhythm Pharmaceuticals for $124 per share.
'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
Bernstein Upgrades AstraZeneca Price Target and Reaffirms Outperform Rating
Bernstein has increased its price target for AstraZeneca PLC while maintaining an 'Outperform' rating on the stock.
AstraZeneca Announces Admission of Further Securities to Trading
AstraZeneca PLC has confirmed the admission of new shares to the London Stock Exchange following employee share scheme activity.
Amgen Just Gave Its Shareholders Great News
Amgen's cancer drug Imdelltra demonstrated significant efficacy when combined with AstraZeneca's Imfinzi, reducing death risk by 58% in advanced lung cancer patients and extending median survival to 21.1 months versus 12.7 months with Imfinzi alone. With Imdelltra already generating 115% growth and a robust pipeline of 22 double-digit growth products, Amgen's stock may have further upside potential despite its 40% year-to-date gain.